News | January 22, 2015

Combination of Integrated Surgery and Radiosurgery for Benign Brain Tumors Validated at Symposium

Novalis Circle community discusses clinical protocols including an emerging comprehensive, multidisciplinary approach in the treatment of benign skull base tumors

January 22, 2015 — The latest Novalis Circle symposium, held at the annual Congress of Neurological Surgeons (CNS) meeting, explored the complex biology, longevity and optimal treatment options for benign skull base tumor patients. Dovetailing with the annual meeting’s focus this year of ‘A Question of Balance,’ the Novalis Circle symposium included cutting-edge technology from Brainlab called Adaptive Hybrid Surgery, whereby clinicians can balance surgical risk and radiation toxicity in the treatment of benign skull base tumors.

Patients who are diagnosed with benign tumors generally have long life expectancies and usually seek intervention only when invasive tumor growth becomes symptomatic. While aggressive surgical interventions have long been the standard treatment, today more than half of all cranial benign growths are alleviated using less aggressive approaches, requiring an adjuvant treatment such as stereotactic radiation. However there is no general consent in determining when a resection is sufficient and when follow-up radiosurgery treatment is safe.

“We conducted a post-treatment review of seven patients with a diverse group of neurosurgeons,” explained Isaac Yang, M.D., neurological surgeon, Ronald Reagan, UCLA Medical Center. “Each surgeon was asked to outline an ideal subtotal surgical resection. When compared side-by-side, the plans were all over the place which confirms the need for objective measures and data on what constitutes an ideal treatment resection for facial nerve preservation in acoustic neuromas.”

“The advent of Adaptive Hybrid Surgery helps us to both control a tumor and preserve function, helping minimize risks during the neurosurgery phase and helping sculpt the radiosurgical target,” presented Andrew Parsa, M.D., Ph.D., chief of the department of neurological surgery, Northwestern University Medical Center and professor of neurological surgery and neurology at Northwestern University Feinberg School of Medicine, Chicago. “We can now achieve the desired tumor control while meeting patient demand for preservation of function.”

Adaptive Hybrid Surgery by Brainlab offers an objective measurement for multi-modal treatment of benign skull base tumors, helping clinicians decide between surgical risks and radiosurgical toxicity when determining the extent of resection. The software provides automatic simulation of follow-up radiation plans, allowing clinicians to optimize residuals to fulfill both surgical and radiosurgical constraints. Information such as tumor coverage and critical dose constraints is intuitively visualized and can be assessed at any time throughout surgery.

“Our first clinical experience with the product underlines the value of Adaptive Hybrid Surgery for multidisciplinary treatments,” said Orin Bloch, M.D., Khatib professor of neurological surgery at Northwestern University Feinberg School of Medicine. “During the surgical intervention, the software allows for continuous update of the extent of resection and in real time simulates the feasibility of adjuvant radiosurgery. With access to this information, we are able to identify an ideal intersection between surgery and radiosurgery, which in turn may allow us to significantly reduce surgical times.”

Prof. Jörg-Christian Tonn, M.D., chief neurosurgeon, Klinikum der Universität München, LMU, presented patient data demonstrating how the software allows clinicians to update a residual tumor volume in real time without the necessity of intraoperative imaging. The data coming out of the first treatments at LMU demonstrated promising results with respect to acquiring intra-operative information about tumor shape and size. He concluded that the new software offers clinicians a good understanding of possible treatment options throughout surgery.

For more information: www.brainlab.com

 

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...